895 related articles for article (PubMed ID: 19515462)
1. 3D-QSAR with the aid of pharmacophore search and docking-based alignments for farnesyltransferase inhibitors.
Vaidya M; Weigt M; Wiese M
Eur J Med Chem; 2009 Oct; 44(10):4070-82. PubMed ID: 19515462
[TBL] [Abstract][Full Text] [Related]
2. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.
Puntambekar DS; Giridhar R; Yadav MR
Eur J Med Chem; 2008 Jan; 43(1):142-54. PubMed ID: 17448576
[TBL] [Abstract][Full Text] [Related]
3. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
Pandey G; Saxena AK
J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
[TBL] [Abstract][Full Text] [Related]
4. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach.
Puntambekar D; Giridhar R; Yadav MR
Bioorg Med Chem Lett; 2006 Apr; 16(7):1821-7. PubMed ID: 16455255
[TBL] [Abstract][Full Text] [Related]
5. Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA.
Puntambekar DS; Giridhar R; Yadav MR
Eur J Med Chem; 2006 Nov; 41(11):1279-92. PubMed ID: 16919851
[TBL] [Abstract][Full Text] [Related]
6. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
7. Modeling ligand-receptor interaction for some MHC class II HLA-DR4 peptide mimetic inhibitors using several molecular docking and 3D QSAR techniques.
Wei HY; Tsai KC; Lin TH
J Chem Inf Model; 2005; 45(5):1343-51. PubMed ID: 16180911
[TBL] [Abstract][Full Text] [Related]
8. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
[TBL] [Abstract][Full Text] [Related]
9. Molecular docking and 3D-QSAR studies of Yersinia protein tyrosine phosphatase YopH inhibitors.
Hu X; Stebbins CE
Bioorg Med Chem; 2005 Feb; 13(4):1101-9. PubMed ID: 15670918
[TBL] [Abstract][Full Text] [Related]
10. 3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues.
Juvale DC; Kulkarni VV; Deokar HS; Wagh NK; Padhye SB; Kulkarni VM
Org Biomol Chem; 2006 Aug; 4(15):2858-68. PubMed ID: 16855733
[TBL] [Abstract][Full Text] [Related]
11. Docking-based 3D-QSAR study for 11beta-HSD1 inhibitors.
Lee JH; Kang NS; Yoo SE
Bioorg Med Chem Lett; 2008 Apr; 18(7):2479-90. PubMed ID: 18314331
[TBL] [Abstract][Full Text] [Related]
12. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
13. Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses.
Guo Y; Xiao J; Guo Z; Chu F; Cheng Y; Wu S
Bioorg Med Chem; 2005 Sep; 13(18):5424-34. PubMed ID: 15963726
[TBL] [Abstract][Full Text] [Related]
14. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
Wei HY; Lu CS; Lin TH
J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210
[TBL] [Abstract][Full Text] [Related]
15. Combined 3D-QSAR modeling and molecular docking study on indolinone derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1.
AbdulHameed MD; Hamza A; Liu J; Zhan CG
J Chem Inf Model; 2008 Sep; 48(9):1760-72. PubMed ID: 18717540
[TBL] [Abstract][Full Text] [Related]
16. Application of 3D QSAR CoMFA/CoMSIA and in silico docking studies on novel renin inhibitors against cardiovascular diseases.
Politi A; Durdagi S; Moutevelis-Minakakis P; Kokotos G; Papadopoulos MG; Mavromoustakos T
Eur J Med Chem; 2009 Sep; 44(9):3703-11. PubMed ID: 19410337
[TBL] [Abstract][Full Text] [Related]
17. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
[TBL] [Abstract][Full Text] [Related]
18. Three-dimensional quantitative structure-activity relationship (3D-QSAR) analyses of choline acetyltransferase inhibitors.
Chandrasekaran V; McGaughey GB; Cavallito CJ; Bowen JP
J Mol Graph Model; 2004 Sep; 23(1):69-76. PubMed ID: 15331055
[TBL] [Abstract][Full Text] [Related]
19. A combined approach of docking and 3D QSAR study of beta-ketoacyl-acyl carrier protein synthase III (FabH) inhibitors.
Ashek A; Cho SJ
Bioorg Med Chem; 2006 Mar; 14(5):1474-82. PubMed ID: 16275103
[TBL] [Abstract][Full Text] [Related]
20. 3D-QSAR studies on tripeptide aldehyde inhibitors of proteasome using CoMFA and CoMSIA methods.
Zhu YQ; Pei JF; Liu ZM; Lai LH; Cui JR; Li RT
Bioorg Med Chem; 2006 Mar; 14(5):1483-96. PubMed ID: 16256351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]